Stereotactic boost on residual disease after external-beam irradiation in clinical stage III non-small cell lung cancer: mature results of stereotactic body radiation therapy post radiation therapy (SBRTpostRT) study

[1] Cheema PK(2019)Perspectives on treatment advances for stage iii locally advanced unresectable non-small-cell lung cancer Curr Oncol 26 37-42

[2] Rothenstein J(2015)Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial p Lancet Oncol 16 187-199

[3] Melosky B(2017)Durvalumab after Chemoradiotherapy in stage III Non–small-cell lung cancer N Engl J Med 377 1919-1929

[4] Bradley JD(2021)Four-year survival with Durvalumab after Chemoradiotherapy in stage III NSCLC—an update from the Pacific trial J Thorac Oncol 16 860-867

[5] Paulus R(1980)A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the radiation therapy oncology group Cancer 45 2744-2753

[6] Komaki R(2017)Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 28 21-2190

[7] Antonia SJ(2010)Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced Non-small-cell lung cancer J Clin Oncol 28 2181-434

[8] Villegas A(2012)Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: An analysis of the radiation therapy oncology group Int J Radiat Oncol Biol Phys 82 425-S2536

[9] Daniel D(2018)Reirradiation for locoregionally recurrent non-small cell lung cancer J Thorac Dis 10 S2522-151

[10] Faivre-Finn C(2019)Patterns of disease progression with Durvalumab in stage III Non-small cell lung cancer (PACIFIC) Int J Radiat Oncol 105 683-538

[1] Cheema PK(2019)Perspectives on treatment advances for stage iii locally advanced unresectable non-small-cell lung cancer Curr Oncol 26 37-42

[2] Rothenstein J(2015)Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial p Lancet Oncol 16 187-199

[3] Melosky B(2017)Durvalumab after Chemoradiotherapy in stage III Non–small-cell lung cancer N Engl J Med 377 1919-1929

[4] Bradley JD(2021)Four-year survival with Durvalumab after Chemoradiotherapy in stage III NSCLC—an update from the Pacific trial J Thorac Oncol 16 860-867

[5] Paulus R(1980)A prospective randomized study of various irradiation doses and fractionation schedules in the treatment of inoperable non-oat-cell carcinoma of the lung. Preliminary report by the radiation therapy oncology group Cancer 45 2744-2753

[6] Komaki R(2017)Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 28 21-2190

[7] Antonia SJ(2010)Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced Non-small-cell lung cancer J Clin Oncol 28 2181-434

[8] Villegas A(2012)Higher biologically effective dose of radiotherapy is associated with improved outcomes for locally advanced non-small cell lung carcinoma treated with chemoradiation: An analysis of the radiation therapy oncology group Int J Radiat Oncol Biol Phys 82 425-S2536

[9] Daniel D(2018)Reirradiation for locoregionally recurrent non-small cell lung cancer J Thorac Dis 10 S2522-151

[10] Faivre-Finn C(2019)Patterns of disease progression with Durvalumab in stage III Non-small cell lung cancer (PACIFIC) Int J Radiat Oncol 105 683-538